目次

Table of Contents

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONAL SCOPE
1.3.3 INCLUSIONS & EXCLUSIONS
1.3.4 YEARS CONSIDERED
1.3.5 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Approach 1: Company revenue analysis (bottom-up approach)
2.2.1.2 Approach 2: MNM repository analysis
2.2.1.3 Approach 3: Primary interviews
2.2.2 SEGMENTAL MARKET ESTIMATION
2.2.2.1 Top-down approach
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 CELL COUNTING MARKET OVERVIEW
4.2 NORTH AMERICA: CELL COUNTING MARKET, BY APPLICATION AND COUNTRY, 2023
4.3 CELL COUNTING MARKET, BY END USER, 2024 VS. 2029
4.4 CELL COUNTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Technological advancements
5.2.1.2 Expanding applications in research and diagnostics
5.2.1.3 Rise in personalized medicine
5.2.2 RESTRAINTS
5.2.2.1 High cost of advanced systems
5.2.3 OPPORTUNITIES
5.2.3.1 Advancements in stem cell research
5.2.3.2 Rising demand for point-of-care diagnostics
5.2.4 CHALLENGES
5.2.4.1 Regulatory and compliance challenges
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.7.1 CELL COUNTING MARKET: RAW MATERIAL PROVIDERS
5.7.2 CELL COUNTING MARKET: PRODUCT MANUFACTURERS/PROVIDERS
5.7.3 CELL COUNTING MARKET: END USERS
5.7.4 CELL COUNTING MARKET: REGULATORY BODIES
5.8 INVESTMENT & FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Automated cell counting
5.9.1.2 Flow cytometry
5.9.1.3 Image-based cell counting
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Cell culture
5.9.2.2 Centrifugation
5.9.2.3 Cell viability testing
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Genomic sequencing
5.9.3.2 Polymerase chain reaction (PCR)
5.9.3.3 Tissue engineering
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 TRADE DATA FOR FLOW CYTOMETERS
5.11.1.1 Import data for flow cytometers
5.11.1.2 Export data for flow cytometers
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 REGULATORY LANDSCAPE
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13.2 REGULATORY FRAMEWORK
5.13.2.1 North America
5.13.2.2 Europe
5.13.2.3 Asia Pacific
5.14 PORTER’S FIVE FORCES ANALYSIS
5.14.1 THREAT OF NEW ENTRANTS
5.14.2 BARGAINING POWER OF SUPPLIERS
5.14.3 BARGAINING POWER OF BUYERS
5.14.4 THREAT OF SUBSTITUTES
5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 BUYING CRITERIA
5.16 IMPACT OF AI/GENERATIVE AI ON CELL COUNTING MARKET
5.16.1 INTRODUCTION
5.16.2 IMPACT OF AI ON CELL COUNTING ECOSYSTEM
5.16.3 FUTURE OF GENERATIVE AI IN CELL COUNTING ECOSYSTEM

6 CELL COUNTING MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 MEDIA, SERA, AND REAGENTS
6.2.1.1 Rising demand for buffers & solvents in research & diagnostics to drive market
6.2.2 ASSAY KITS
6.2.2.1 Cell viability assays
6.2.2.1.1 Critical evaluation of cytotoxicity to drive segment growth
6.2.2.2 Cell staining assays
6.2.2.2.1 Advancements in imaging systems and flow cytometry to boost demand
6.2.2.3 Cytotoxicity assays
6.2.2.3.1 Provision of insights into cell viability & membrane integrity to fuel uptake
6.2.2.4 Calorimetric assays
6.2.2.4.1 Assessment of biochemical reactions to drive segment growth
6.2.2.5 Other assays
6.2.3 MICROPLATES
6.2.3.1 Rising utilization in high-throughput research to drive market
6.2.4 ACCESSORIES
6.2.4.1 Increasing demand for essential components like sensors & electrical accessories to support market growth
6.2.5 OTHER CONSUMABLES
6.3 INSTRUMENTS
6.3.1 SPECTROPHOTOMETERS
6.3.1.1 Single-mode readers
6.3.1.1.1 Wide utilization across research & industrial labs to boost demand
6.3.1.2 Multi-mode readers
6.3.1.2.1 Advanced data visualization software to support segment growth
6.3.2 FLOW CYTOMETERS
6.3.2.1 Wide uptake in clinical & research applications to propel market
6.3.3 HEMATOLOGY ANALYZERS
6.3.3.1 Fully automated Analyzers
6.3.3.1.1 High yield with minimal manual intervention to drive segment growth
6.3.3.2 Semi-automated Analyzers
6.3.3.2.1 Cost-efficiency and compact size to fuel uptake
6.3.4 CELL COUNTERS
6.3.4.1 Cell Counters, by mode
6.3.4.1.1 Automated cell counters
6.3.4.1.1.1 Reliable and rapid results to boost demand
6.3.4.1.2 Manual cell counters
6.3.4.1.2.1 High accuracy to support segment growth
6.3.4.2 Cell Counters, by technique
6.3.4.2.1 Fluorescence-based cell counters
6.3.4.2.1.1 Precise quantification of cell populations to drive segment growth
6.3.4.2.2 Image-based cell counters
6.3.4.2.2.1 Integration of image-based systems into laboratory workflows to fuel uptake
6.3.4.2.3 Brightfield cell counters
6.3.4.2.3.1 Increasing demand for efficient and cost-effective cell counting solutions to boost demand
6.3.4.2.4 Other cell counters
6.3.5 MICROSCOPES
6.3.5.1 Advancements in cell-based therapies to drive market
6.3.6 OTHER INSTRUMENTS

7 CELL COUNTING MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 RESEARCH APPLICATIONS
7.2.1 CANCER RESEARCH
7.2.1.1 Rising prevalence of cancer and growing focus on early detection to drive market
7.2.2 IMMUNOLOGY RESEARCH
7.2.2.1 Rising prevalence of autoimmune diseases to fuel market
7.2.3 NEUROLOGY RESEARCH
7.2.3.1 Rising incidence of neurological disorders to propel market
7.2.4 STEM CELL RESEARCH
7.2.4.1 Favorable R&D investments to boost demand
7.2.5 OTHER RESEARCH APPLICATIONS
7.3 MEDICAL APPLICATIONS
7.3.1 HEMATOLOGY & COMPLETE BLOOD COUNT
7.3.1.1 Uptake of hematology analyzers in diagnosis of anemia & leukemia to drive market
7.3.2 NON-INVASIVE PRENATAL DIAGNOSTICS
7.3.2.1 Provision of critical insights into fetal health to support market growth
7.3.3 IN VITRO FERTILIZATION
7.3.3.1 Increasing prevalence of infertility and advancements in assisted reproductive technologies to drive market
7.3.4 CIRCULATING TUMOR CELL DETECTION
7.3.4.1 Growing focus on precision oncology and liquid biopsies to fuel market
7.3.5 OTHER MEDICAL APPLICATIONS
7.4 OTHER INDUSTRIAL APPLICATIONS

8 CELL COUNTING MARKET, BY END USER
8.1 INTRODUCTION
8.2 ACADEMIC & RESEARCH INSTITUTES
8.2.1 ADVANCEMENTS IN STEM CELL RESEARCH AND GROWING FOCUS ON LIFE SCIENCES TO PROPEL MARKET
8.3 HOSPITALS & DIAGNOSTIC LABORATORIES
8.3.1 RISING PREVALENCE OF CHRONIC & INFECTIOUS DISEASES TO DRIVE MARKET
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.4.1 EXPANDING PIPELINE OF BIOLOGICS TO FUEL MARKET
8.5 OTHER END USERS

9 CELL COUNTING MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 US to dominate North American cell counting market during study period
9.2.3 CANADA
9.2.3.1 Rising demand for advanced research tools in biopharmaceutical and academic research to drive market
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Robust biopharma manufacturing and substantial federal R&D investments to aid market growth
9.3.3 UK
9.3.3.1 Favorable government funding for pharmaceutical & biotechnology research to support market growth
9.3.4 FRANCE
9.3.4.1 Favorable government initiatives and increased investments by foreign pharmaceutical companies to aid market growth
9.3.5 ITALY
9.3.5.1 Advanced life science research biomanufacturing facilities to augment market growth
9.3.6 SPAIN
9.3.6.1 Emphasis on biopharmaceutical innovation and cancer research to stimulate market growth
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Growing prominence in clinical trials and biologics production to fuel market growth
9.4.3 JAPAN
9.4.3.1 High availability of funding and technological expertise to support market growth
9.4.4 INDIA
9.4.4.1 Favorable FDI regulations in pharmaceutical industry to boost market growth
9.4.5 SOUTH KOREA
9.4.5.1 Increasing healthcare expenditure and rising government R&D budget to fuel uptake
9.4.6 AUSTRALIA
9.4.6.1 Focus on translational research and clinical trials in cancer therapies and regenerative medicines to drive market
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Robust healthcare infrastructure and high prevalence of chronic diseases to propel demand for cell-counting technologies
9.5.3 MEXICO
9.5.3.1 Burgeoning pharmaceutical industry and increased collaborations among industry leaders to propel market growth
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
9.6.2 GCC COUNTRIES
9.6.2.1 Saudi Arabia
9.6.2.1.1 Growing focus on public-private partnerships and rising investments in healthcare modernization to drive market
9.6.2.2 UAE
9.6.2.2.1 World-class healthcare infrastructure to drive adoption of cell counting technologies
9.6.2.3 Rest of GCC Countries
9.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 HIGH GOVERNMENT HEALTHCARE BUDGET AND INCREASED POPULARITY AS BIOTECH HUB TO SUPPORT MARKET GROWTH
9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL COUNTING MARKET
10.3 REVENUE ANALYSIS, 2019-2023
10.4 MARKET SHARE ANALYSIS, 2023
10.5 COMPANY VALUATION AND FINANCIAL METRICS
10.5.1 COMPANY VALUATION
10.5.2 FINANCIAL METRICS
10.6 BRAND/PRODUCT COMPARISON
10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
10.7.1 STARS
10.7.2 EMERGING LEADERS
10.7.3 PERVASIVE PLAYERS
10.7.4 PARTICIPANTS
10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
10.7.5.1 Company footprint
10.7.5.2 Region footprint
10.7.5.3 Product footprint
10.7.5.4 Application footprint
10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
10.8.1 PROGRESSIVE COMPANIES
10.8.2 RESPONSIVE COMPANIES
10.8.3 DYNAMIC COMPANIES
10.8.4 STARTING BLOCKS
10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.8.5.1 Detailed list of key startups/SMEs
10.8.5.2 Competitive benchmarking of startups/SMEs
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT LAUNCHES
10.9.2 DEALS
10.9.3 EXPANSIONS

11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 DANAHER CORPORATION
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Product launches
11.1.1.3.2 Deals
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses and competitive threats
11.1.2 THERMO FISHER SCIENTIFIC INC.
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Deals
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses and competitive threats
11.1.3 AGILENT TECHNOLOGIES, INC.
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Expansions
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses and competitive threats
11.1.4 BD
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Product launches
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses and competitive threats
11.1.5 ABBOTT LABORATORIES
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 MnM view
11.1.5.3.1 Key strengths
11.1.5.3.2 Strategic choices
11.1.5.3.3 Weaknesses and competitive threats
11.1.6 MERCK KGAA
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Deals
11.1.6.3.2 Expansions
11.1.7 REVVITY
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.7.3 Recent developments
11.1.7.3.1 Product launches
11.1.7.3.2 Deals
11.1.8 BIO-RAD LABORATORIES, INC.
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.9 CORNING INCORPORATED
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.10 TECAN TRADING AG
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.11 BOULE
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.11.3 Recent developments
11.1.11.3.1 Deals
11.1.12 HORIBA
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.12.3 Recent developments
11.1.12.3.1 Product launches
11.1.13 SIEMENS HEALTHINEERS AG
11.1.13.1 Business overview
11.1.13.2 Products offered
11.1.13.3 Recent developments
11.1.13.3.1 Product launches
11.1.14 EVIDENT
11.1.14.1 Business overview
11.1.14.2 Products offered
11.1.14.3 Recent developments
11.1.14.3.1 Product launches
11.1.14.3.2 Deals
11.1.14.3.3 Expansions
11.1.15 F. HOFFMANN-LA ROCHE LTD
11.1.15.1 Business overview
11.1.15.2 Products offered
11.1.16 SYSMEX CORPORATION
11.1.16.1 Business overview
11.1.16.2 Products offered
11.1.16.3 Recent developments
11.1.16.3.1 Product launches
11.1.16.3.2 Deals
11.2 OTHER PLAYERS
11.2.1 CYTEK BIOSCIENCES
11.2.2 TIP BIOSYSTEMS
11.2.3 ALIGNED GENETICS
11.2.4 YOKOGAWA ELECTRIC CORPORATION
11.2.5 COLE-PARMER INSTRUMENT COMPANY, LLC
11.2.6 MILTENYI BIOTEC
11.2.7 LONZA
11.2.8 BIOLINE TECHNOLOGIES
11.2.9 NIKON CORPORATION
11.2.10 AXON BIOSYTEMS, INC.
11.2.11 CREATIVE BIOARRAY

12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS